Genoss drug-eluting stent (DES)	Promus Element	no target lesion revascularization (TLR)	14067	14158	the rate of death, MI, TLR, and TVR at 9 months were not significantly different (Table 5).
Genoss drug-eluting stent (DES)	Promus Element	no myocardial infarction (MI)	13851	13942	For clinical outcomes, there were no MI or stent thrombosis events during 9-month follow-up
Genoss drug-eluting stent (DES)	Promus Element	rates of death	1332	1483	The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different.
Genoss drug-eluting stent (DES)	Promus Element	no stent thrombosis	13851	13942	For clinical outcomes, there were no MI or stent thrombosis events during 9-month follow-up
Genoss drug-eluting stent (DES)	Promus Element	no stent thrombosis	1279	1331	There was no MI or stent thrombosis in either group.
Genoss drug-eluting stent (DES)	Promus Element	no target lesion revascularization (TLR)	1332	1483	The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different.
Genoss drug-eluting stent (DES)	Promus Element	no myocardial infarction (MI)	1279	1331	There was no MI or stent thrombosis in either group.
Genoss drug-eluting stent (DES)	Promus Element	In-stent late lumen loss at 9 months	1150	1277	In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11±0.25 vs. 0.16±0.43 mm, p=0.567)
